FDA clears targeted cholangiocarcinoma therapy
-
By
-
Kathryn Wighton
-
September 24, 2026
-
2 min
By
Kathryn Wighton
September 24, 2026
Optical analysis of resection-margin tissue identified tumor infiltration as the strongest contributor to predictions of where glioblastoma later recurred.
October 15, 2026
A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.
September 8, 2026
Postmortem multiomic analyses showed more quiescent neural stem cells and fewer neuroblasts, alongside broader hippocampal molecular changes.
August 26, 2026